Understanding the connection between aortic stenosis and TAVI

Aortic stenosis is a common and potentially life-threatening condition characterised by the narrowing of the aortic valve opening, which restricts blood flow from the heart to the rest of the body. It typically results from age-related calcification, although it can also be caused by congenital defects or rheumatic fever. Symptoms include chest pain, shortness of breath, fatigue, and fainting. Left untreated, severe aortic stenosis can lead to heart failure and increased mortality.

Transcatheter Aortic Valve Implantation (TAVI), also known as Transcatheter Aortic Valve Replacement (TAVR), is a minimally invasive procedure developed to treat aortic stenosis in patients who are at high or prohibitive surgical risk. TAVI involves inserting a catheter through the femoral artery (or sometimes through other access points) to deliver and implant a new valve within the diseased aortic valve, effectively restoring normal blood flow.

The development of TAVI has revolutionized the treatment of aortic stenosis, especially in elderly or frail patients who may not tolerate open-heart surgery. Clinical studies have shown that TAVI can significantly improve survival rates, reduce symptoms, and enhance quality of life in these patients.

Initially reserved for high-risk populations, TAVI is now being considered for intermediate- and even low-risk patients, thanks to advancements in technology and growing clinical evidence. Despite its benefits, TAVI is not suitable for everyone. Patients are evaluated through a multidisciplinary heart team that considers factors such as anatomy, comorbidities, and life expectancy.

In summary, aortic stenosis and TAVI are closely linked in modern cardiology. As the population ages and diagnostic capabilities improve, TAVI continues to emerge as a critical solution for managing this serious heart valve condition, offering hope and improved outcomes for thousands of patients worldwide.